192 related articles for article (PubMed ID: 20141428)
21. The role of B cells in the pathogenesis of graft-versus-host disease.
Shimabukuro-Vornhagen A; Hallek MJ; Storb RF; von Bergwelt-Baildon MS
Blood; 2009 Dec; 114(24):4919-27. PubMed ID: 19749094
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
23. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
Giralt S
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
[TBL] [Abstract][Full Text] [Related]
24. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.
Marini BL; Markstrom D; Frame D
J Oncol Pharm Pract; 2017 Jun; 23(4):255-263. PubMed ID: 26970572
[TBL] [Abstract][Full Text] [Related]
25. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.
van Dorp S; Resemann H; te Boome L; Pietersma F; van Baarle D; Gmelig-Meyling F; de Weger R; Petersen E; Minnema M; Lokhorst H; Ebeling S; Beijn SJ; Knol EF; van Dijk M; Meijer E; Kuball J
Haematologica; 2011 Sep; 96(9):1380-4. PubMed ID: 21546493
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies to treat graft-versus-host disease.
Carella AM; D'Arena G; Cascavilla N
Mini Rev Med Chem; 2011 Jun; 11(6):473-9. PubMed ID: 21561410
[TBL] [Abstract][Full Text] [Related]
27. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H; Sahaf B; Miklos DB
Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Ceppi F; Duval M; Teira P; Therrien R; Ovetchkine P; Mallette B; Bittencourt H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e319-21. PubMed ID: 24977404
[TBL] [Abstract][Full Text] [Related]
30. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
31. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
32. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
34. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.
Dominietto A; Tedone E; Soracco M; Bruno B; Raiola AM; Van Lint MT; Geroldi S; Lamparelli T; Galano B; Gualandi F; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2012 Jan; 47(1):101-6. PubMed ID: 21460867
[TBL] [Abstract][Full Text] [Related]
35. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
36. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
37. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
[TBL] [Abstract][Full Text] [Related]
38. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]